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Molecular diagnostics
the changing culture of medical microbiology
Susan Bullman, Brigid Lucey* and Roy D. Sleator
Department of Biological Sciences, Cork Institute of Technology; Cork, Ireland
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Diagnostic molecular biology is arguably the fastest growing area in current laboratory-based medicine. Growth of the so
called ‘omics’ technologies has, over the last decade, led to a gradual migration away from the ‘one test, one pathogen’
paradigm, toward multiplex approaches to infectious disease diagnosis, which have led to significant improvements in
clinical diagnostics and ultimately improved patient care.
Introduction
Until recently the tools available to the
clinical microbiologist were antiquated in
comparison to most other biological speci-
alties. With a basic technology essentially
unchanged for decades, clinical microbio-
logists were limited in which organisms
they could detect and as a result, it is likely
that a multitude of infections were left
undiagnosed. After an enduring wait, the
“Molecular Revolution”, which has already
significantly impacted other branches of
microbiology, is now being felt in clinical
microbiology laboratories and promises to
propel this discipline into the 21st century.
At last, traditional culture-based infection
diagnostic techniques are gradually being
replaced by more advanced molecular
detection methods, in a movement which
has been hastened by rapid advances in
genomics and bioinformatics. Herein, we
examine the challenges, considerations
and some new developments in the field
of molecular clinical microbiology that
are likely to affect, and be affected by, the
medical scientist as part of the collective
drive to improve healthcare.
Traditionally, the gold standard for
diagnosis in the clinical microbiology
laboratory has been culture—the organism
is isolated and identified definitively
followed by the generation of a patient
report. It is widely accepted that the earlier
an accurate microbiology report can be
generated, the more significant the impact
it is likely to have on patient care. How-
ever, sample culture takes a minimum of
18 h, followed by further subculture for
identification and susceptibility testing.
It is likely that these gold standards for
diagnosis have evolved on the basis of the
most sensitive and specific techniques
available at the time. Now in the “omics
era”, the time has come for clinical
scientists to reassess the components of
their “diagnostic tool box” to help improve
infectious disease management. Technolo-
gical advances, such as molecular diagnost-
ics, offer the possibility of rapid reporting
and improvement of the impact of clinical
microbiology on patient management.
The First Wave of Molecular
Diagnostic in the Clinical
Microbiology Laboratory
Currently, in clinical diagnostic laborat-
ories, molecular methods are emerging as
the frontrunners in the detection of parti-
cular pathogens and thus, are beginning
to replace traditional culture-based techni-
ques. One example of where molecular-
based diagnosis has already become well
established is in the detection of Chlamy-
dia trachomatis infection. The 1980s saw
direct fluorescent antibody (DFA) tests
and enzyme immunoassay replace tissue
culture—the gold standard of the time—
particularly in the absence of specialized
and time-consuming tissue culture facili-
ties. In the 1990s the commercial deve-
lopment of Polymerase Chain Reaction
(PCR) and Ligase Chain Reaction (LCR)
methods for chlamydia detection,
although more expensive than DFA/EIA,
were nonetheless shown to be comparable
to tissue culture in terms of sensitivity and
specificity.1-3 More recently, Real Time
PCR (RT-PCR) methods for chlamydia
detection have been developed, and large
throughput of samples and commercial
competition have helped to drive down
costs incurred by the testing laboratory, to
make this a routinely-used method. The
widespread use of relatively user-friendly
molecular methods for chlamydia testing
may have helped to pave the way, albeit
slowly, for the uptake of further molecular
assays as they became available.
Moreover, many of these techniques
facilitate post-amplification analysis on the
products. Such techniques include melt-
curve analysis (MCA), in which the
resolution relies on the difference in the
melting temperatures (Tm) between ampli-
cons. This provides different information,
depending on the type of probe used.
High resolution MCA may be used to
detect Single Nucleotide Polymorphisms
(SNPs) when using non-specific DNA
binding dyes, facilitating speciation and
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source identification after broad range
nucleic acid amplification.4 The use of
SNP analysis within the diagnostic micro-
biology laboratory is likely to have a
significant contribution to the field of
epidemiology. Moreover, high resolution
MCA has been used in the detection of
antibiotic resistant genes in bacteria such
as Hemophilus influenzae, Neisseria gonor-
rhoeae and multi-drug resistant Mycobac-
terium tuberculosis.5
The Cost of Molecular Diagnostics:
A Worthy Price to Pay?
The fact that certain routine diagnostic
tests remain traditionally culture-based is
dictated largely by the cost of introducing
new techniques, staff training and increa-
sed space requirements. Such factors are all
too often the primary causes for stagnation
when implementing novel molecular dia-
gnostics in the clinical laboratory.6
The development of a CE-IVD assay,
for example, incorporates a number of
extensive phases including research, ana-
lytical and clinical validation, certification
and ongoing post-market approval require-
ments. Furthermore, significant costs are
incurred from developing novel technolo-
gies for an assay or through license fees for
the use of patented technologies. As an
example, a multiplex real-time PCR assay
may incur license fees for gene targets,
fluorophores, quenchers, modified poly-
merases, amplification technology and pre-
paration processes such as lyophilization.
Furthermore, the cost of Good Manufactur-
ing Practice (GMP) grade raw materials,
manufacturing, direct/indirect distribution
and product support also bring with them
important financial considerations.
However, it is likely that the economy
of scale that comes from using common
platforms and technicians specifically
trained for molecular diagnostics facilitate
an increase in workload without the
corresponding increase in laboratory staff.7
Moreover, molecular diagnostics easily
accommodate the concept of consolida-
tion, integration and automation. Also,
such tests fit seamlessly into the model
of an integrated laboratory which may in
turn loosen the link between the micro-
biologist and the microbiology test, argu-
ably to the benefit of the patient.7
It appears that the benefits of these
assays are less likely to be found in the
laboratory and more likely to be seen at
the patient level by the clinician, health-
care provider or administrator.7,8 For
example, the rapid detection and char-
acterization of an infecting pathogen may
allow the clinician an opportunity to tailor
antimicrobial therapy and aid the use of
narrow-spectrum antibiotics as opposed to
broad spectrum reagents.9,10 In compar-
ison to traditional microbiology culture,
molecular diagnostics facilitates rapid iden-
tification of at risk individuals, allows for
early detection of asymptomatic disease
and facilitates the monitoring of treatment
which may ultimately promote new drug
design and development.9-12 Such improve-
ments in patient care and treatment will
not only reduce the spread of antimicro-
bial-resistant organisms but is likely to
reduce the adverse effects of broad
spectrum drugs; including nosocomial
antibiotic associated diarrhea (AAD) as a
result of opportunistic C. difficile infec-
tion.13 In effect this will have a rippling
outcome on patient hospital duration and
reduce the number of hospital beds
occupied by patients who contract noso-
comial infections.
It is apparent that new and advanced
methods of molecular diagnostics are
shifting the way in which we practice
clinical microbiology, which in turn are
likely to affect the practice of medicine in
general.8 While this “Molecular Revolu-
tion” represents an exciting departure from
the norm, it remains the responsibility of
both the clinician and the clinical scientist
to ensure that these tests are used appro-
priately.14 The large amount of data that
may be obtained from patient samples
using such molecular methods must be
monitored carefully and strict ethical
guidelines must be constructed for such
tests.15 Furthermore, the abuse of this
technology has serious implications for
cost as well as patient care due to the
possibilities of false positive or false
negative reactions.16
Effecting New Strategies
for Laboratory-Based Diagnosis
Overall, the recent rapid advances in
molecular-based detection methods,
underline the need for tripartite collabora-
tions between clinical, research and com-
mercial laboratories (Fig. 1). Collectively,
we can hope to continue to design and
develop ever-more sophisticated, rapid
and automated assays targeting clinically
significant organisms while still ideally
conforming to the working day of the
medical scientist. There is a fundamental
need to identify those pathogens, both
established and emerging, which impose
the highest clinical and economic cost.
Thus, the source of infection can be
identified and effective infection control
measures implemented swiftly enough to
be of use.
A serendipitous consequence of
molecular-based detection methods is
that, in addition to their speed, high
specificity and sensitivity, they may also
facilitate the detection of previously
unknown and undetected pathogens. In
support of this has been the identification
of Campylobacter ureolyticus as a novel
gastrointestinal putative pathogen using a
commercial multiplex-based PCR detec-
tion system in the Republic of Ireland.17,18
Given that campylobacter is currently the
most commonly-isolated bacterial patho-
gen worldwide, the detection of a new
species in more than 20% of the total
campylobacter detections among patients
with acute gastroenteritis is a significant
finding.
Indeed, work in our laboratory has
shown that C. ureolyticus now surpasses
C. coli as the second most common
campylobacter species in the feces of
patients presenting with gastroenteritis
(at least in Southern Ireland).19 This
organism, which is incapable of growth
on routine campylobacter culture, to the
best of our knowledge, has never pre-
viously been reported in the faeces of
patients with diarrheal illness. This is an
example of the benefit that molecular
diagnostics can bring to bear on the
detection of fastidious organisms, which
by routine culture would have been
otherwise reported as false negatives.
Merely detecting a bacterium or virus in
a clinical sample does not of course
distinguish it a true pathogen or as an
innocent bystander, an innocuous com-
ponent of the normal flora. However, as
in the case of C. ureolyticus, whereby the
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clinical syndrome of the patients and
corresponding microbial detections are
linked, a compelling case might well be
made for causality. Interestingly, the
majority of fecal samples (. 90%)
routinely tested for bacterial enteric patho-
gens return negative results, begging the
question—what else is being missed?
The Dynamic Nature
of Infectious Disease
Pallen and Wren20 refer to bacterial
genomes as “molecular palimpsests”,
whereby the variable region of the
genome displays the scars of recurring
rounds of gene acquisition and erosion.
Recent studies have highlighted the
unexpected large genetic diversity between
strains of the same species, thus blurring
our definition of species boundaries.21
The merging of phylogenetics and
genomics to give phylogenomics has
revolutionized comparative genomics in
bacteriology.22,23
Figure 1. Microarray design, production and application; A Tripartite Collaboration between the Clinical, Research and Commercial Laboratories. (A) In
the diagnosis and investigation of infectious disease, clinical laboratories receive patient samples from various anatomical sites with polymicrobial
populations. A DNA extraction is conducted on the patient samples received and the single stranded DNA is labeled with a fluorescent tag, a single
probe mixture or multiple probe mixture as seen in (A), maybe prepared using multiple fluorescent labels in a multi-color DNA and RNA hybridization.
The probe sample can then be added to a commercial “disease-specific” microarray which contains a repertoire of genus and species specific
oligonucleotides. The probe sample is incubated with the microarray in a hybridization station to allow molecular binding. After the probe binding
reaction is complete, the microarray is washed to remove unbound material and fluorescence is observed based upon the hybridization of the labeled
DNA in the patient's sample to complementary immobilized oligonucleotides on the microarray. A microarray scanning or imaging device is used to
acquire the signals, followed by signal quantification yielding data. Strict inclusion and exclusion criteria are applied to the data to ensure statistical
relevance. Computational programs will then apply statistical analysis on the data obtained as to whether or not clinically significant organisms were
present in the patient sample, ultimately resulting in the generation of a patient report and the diagnosis or exclusion of infection. (B) In order to design
beneficial diagnostic “disease-specific” microarrays, the research laboratories will communicate with the clinical laboratories, relating to sample types
and clinically significant organisms which would be of interest in human health and disease. Clinical laboratories may provide research laboratories with
specimen samples containing polymicrobial populations and a biological matrix which is representative of various states of health and disease. DNA
extraction would be performed, followed by DNA sequencing and phylogentic analysis of the organisms detected. By assessing and comparing the pan
genomes of species belonging to a particular genus and even various strains of a certain species, candidate genes can be selected that represent the
core genome of the organisms of interest, along with identifying strain differences represented by accessory genes. This facilitates the design of a
microarray that is capable of specific microbial species identification from a polymicrobial sample. (C) The microarrays designed by the research
laboratories may then be developed further by commercial laboratories. Additional insilico analysis may refine the selected candidate genes and result in
the synthesis of genus/ species/ strain specific oligonucleotide probes. Such probes can then be robotically immobilized onto glass slide. The resulting
microarray will then be subjected to extensive development phases including research, analytical and clinical validation, certification and ongoing post-
market approval requirements. Once the particular microarray is available commercially, a feedback system may be in place between the commercial
laboratories, the clinical laboratories and the research laboratories relating to assay performance in the clinical setting and possible measures for
improvement, in addition to the alteration of such assays to rapidly respond to emerging pathogens.
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Comparative phylogenomics presents
us with a genome profile for an organ-
ism, giving it a signature genome.23
This technology can be employed in
the research laboratory to identify new
“reporter genes” for bacterial identifica-
tion and thus the diagnosis of infection.24
The phenomenon of horizontal gene
transfer, pathoadaptive mutations and
genome decay further emphasizes the
likelihood of detecting unexpected organ-
isms as the causative agents in human
disease.20,21,25 The core of nucleic acid
testing in the clinical laboratory is PCR
and although it provides rapid clinical
information with a high degree of sens-
itivity and specificity, the adage “you only
find what you’re looking for” applies.26
As Rappuoli et al. state, “dozens of new
infectious diseases are expected to emerge
in the coming decade”,27 in order to rise to
this challenge and combat the dynamic
nature of infectious disease we will most
certainly be required to develop more
comprehensive identification methods in
response to new microbial variables such
as chromosomal shuffling. One such
approach involves the use of DNA micro-
array technology, which enables whole-
scale comparisons of bacterial genomes,
thus bringing comparative phylogenomics
to the forefront.21 Furthermore, as infec-
tions can sometimes be polymicrobial, in
particular many enteric infections,19 the
limit of traditional molecular multiplexing
is defined by the maximal primer concen-
tration that can be accommodated in a
primer mix.
The detection of putative novel poly-
microbial infection is likely, at least in the
short term, to be restricted by its estab-
lishment as the definitive cause of disease.
Realistically, new findings are unlikely to
be accepted without first fulfilling a revised
version of Koch’s postulates, such as that
proposed by Fredericks and Relman in
199628 or Molecular Koch’s Postulates
proposed by Falkow in 1988.29
The Use of Microarray Technology
in Diagnostic Microbiology
Although microarray technology was
originally developed for gene expression
studies, it has been adapted to the rapid
assessment of the composition of complex
microbial populations in array compara-
tive genomic hybridization (aCGH).30 It
has been reported that the use of “limited
microarrays” for the assessment of numer-
ous genetic targets after either a multi-
plex reaction or a broad range PCR, at
present is one of the most promising areas
in molecular diagnostics.8 Furthermore,
DNA microarrays enable a much larger-
scale comparison of bacterial genomes
than conventional PCR and form a
platform for comparative phylogenomics.21
Regardless of its technical format, this
technology consists of numerous indi-
vidual probe-target hybridization reactions
that are tested for simultaneously. Various
microarrays have been scaled down from
large platforms to smaller-sized versions
that address clinically important issues
that may require multiple results. Regard-
ing microarray design, the overall aim for
incorporating this technology into the
clinical laboratories is to design disease-
specific arrays that contain approximately
30–40 hybridization sites with genus- or
species-level probe sites for the common
pathogens and broad-range bacterial
probes for the rare pathogens. For exam-
ple Luminex markets the FDA approved
“Luminex RVPTM Assay”, a panel of
probes for detecting 12 viral agents of
upper respiratory tract infections currently
being used in clinical microbiology dia-
gnostics. Additionally a DNA Microarray
for the detection of bacterial pathogens
in patients with chronic obstructive
pulmonary disease has been described.31
Furthermore, in situations where a spe-
cialist medical facility requires simultan-
eous testing for a selection of infections
pertaining to its patients, it is becoming
feasible to order a commercial custom-
designed microarray from companies
such as Bechman Coulter Genomics,
Massachusetts or Arrayit Corporation,
Silicon Valley, California.
In premise, by assessing and comparing
the pan genomes of species belonging to
a particular genus and even various strains
of a certain species, we can carefully select
candidate genes representing the core
genome along with identifying strain
differences represented by accessory
genes, thus allowing for specific micro-
bial species identification from a poly-
microbial sample. Willenbrock et al.30 for
example, describes a novel pan-genome
microarray encompassing 24 E. coli and
8 Shigella genomes with the aim of
identifying emerging pathogens. Another
beneficial microarray to the clinical
laboratories was described by Wang
et al.,32 a long oligonucleotide DNA
microarray capable of simultaneously
detecting hundreds of viruses. In this
particular microarray, elements were
selected from highly conserved regions
within viral families which still enabled
individual viruses that were not explicitly
represented on the microarray to be
detected, thereby facilitating new un-
sequenced or uncharacterized virus discov-
ery. Thus, DNA-microarrays composed of
carefully selected viral sequences, coupled
to a random amplification step allows for
a broad reaching and unbiased detection
strategy.
Moreover, the increase in genome
sequencing coupled with methods such
as suppression subtractive hybridization
which allows for the differential compar-
ison of bacterial genomes, allow us to
move toward “pan arrays” or “whole-pan-
genome tiling arrays”.33,34
Such advances are radically transform-
ing our current view of multiplex labor-
atory testing and will hopefully expand
pathogen detection to include bacterial
population-based analysis and host speci-
fic responses. Disease-specific microarrays,
which may be a microbial detection array
and/or a microbial functional gene array,
will rely on using these formats after broad
range PCR, multiplex PCR or a combina-
tion of such assays. Such an array would,
in a single post-amplification assay, address
all the most common etiological agents
that may be responsible for the infec-
tion.35,36 Thus, we must aim to identify a
repertoire of candidate genes that will
allow for the sensitive, selective and
accurate identification of those organisms
causing human disease; a challenge for
both the research and medical scientist
alike.
As the panels of infectious agents are
continually expanding, coupled with the
aid of phylogenomics to decipher the
genetic clues to bacterial virulence and
host specificity, a readily modifiable
approach to multiparameter testing in
diagnostic clinical laboratories is dawning
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and along with it the advent of persona-
lized medicine.
Personalised Medicine:
The Future of Biomedicine
The era of personalised or individualised
medicine began in earnest with the publi-
cation of the draft human genome in
2001.37-40 Genomic studies have tended
to focus on the host genome, to identify
host genes that are expressed after bacter-
ial invasion or that are associated with
susceptibility to infection.20
Taking into consideration that bacterial
cells outnumber human cells by a factor of
10 to 1, one particular area that may
contribute to a personalized approach in
diagnostics is the investigation of the
microbial species usually assigned com-
mensal status at particular sites of the
body.41 The Human Microbiome Project
(HMP) has resulted in substantial revela-
tions regarding human and microbial
interactions and the development of
disease.42 The focus of the HMP was to
define a core set of microbes associated
with the human body; variations in this
“core microbiome” may eventually be
correlated with changes in human health.43
For example a number of studies investi-
gating the contribution of microbial
populations to human health and disease
have reported a 10-fold shift in the ratio
of Firmicutes to Bacteroides species in the
gastrointestinal tract (GI) of obese patients
in comparison to their lean counterparts.44
Moreover, it is estimated that the GI tract
is occupied by an excess of 1014 micro-
organisms, representing a vast ecosystem of
almost 1,000 different bacterial species.44
Additionally, the “metagenome” of the
microbial species resident in the various
sites of the human body is estimated to
be 100-fold greater in terms of gene con-
tent than the human genome. This diverse
and complex collection of genes encodes
a wide array of biochemical and physio-
logical functions that may benefit the host
as well as the neighboring microbes.45
Acknowledging the strength and rapid
response of the human immune system
to infectious agents, the ability of these
microbial populations to exist in synergy
within the human host cannot be
overlooked and we must redirect our
assessment of human health toward the
“human superorganism” whereby diag-
nostic and prognostic assessments should
recognize the contribution of not only
mammalian cells but also our constituent
microbial cells to human health.46
Commercial companies such as Human
Microbe Identification Microarray core
(MIM) (based at The Forsyth Institute,
Cambridge, Massachusetts, USA) promise
to allow for the rapid determination of
bacterial profiles, to the species level,
from clinical samples of the human oral
cavity.47 Although currently only permit-
ted for use in research laboratories, this
Human Oral Microbe Identification
Microarray (HOMIM) enables the sim-
ultaneous detection of approximately 300
of the most prevalent bacterial species in
the oral cavity, thus permitting the com-
parison of bacterial associations in health
vs. disease.47-50 At present, their research
has linked variations in oral microbial
populations not only with periodontal
health but also with inflammatory bowel
disease and pancreatic diseases includ-
ing pancreatic cancer.49,50 Furthermore,
Forsyth state on their website (mim.
forsyth.org) that they are currently deve-
loping microarrays to detect the combina-
tions of bacterial species in the human
gastrointestinal tract, which in conjunc-
tion with the findings of the HMP are
likely to provide valuable insights into the
“human superorganism”.
With an alarming annual average of
more than 13 million deaths worldwide
from infectious diseases,51 partially due
to an increase in antibiotic resistance in
infectious organisms, new approaches,
such as pharmacogenomics, tailoring
host-pathogen-drug interactions are
emerging to circumvent such resistance.
Pharmacogenomics, a promising area in
personalized medicine introduces the con-
cept of molecular markers (biomarkers)
to assess drug efficacy, safety and disease
risk.52 It promises to predict the indi-
vidual outcome of specific therapies in
addition to broad pharmacological strat-
egies while considering both host and
pathogen to determine the “right drug”
for the “right patient” at the “right time”.
For example individualized antibiotic
treatment has already been initiated by
considering drug-metabolism enzyme
variants.51 Moreover, recent studies are
extending such treatment by focusing on
SNP’s, haplotyping, particular gene copy
numbers and the individual response of
the host’s immune system.52-54 Variations
in the human multidrug-resistance gene-1
(MDR1) for example, such as a C to T
SNP at position 3435, can predict therapy
response to highly active antiretroviral
therapy (HAART) in HIV-1 patients.55
Furthermore, although abacavir is an
effective treatment for HIV, fatal hyper-
sensitivity reactions have been linked with
particular HLA alleles.56
A significant goal for personalized/
individualized medicine is to permit a
shift in emphasis from disease treatment
to prevention.57 However, despite the
aforementioned advances, it is fair to say
that personalized medicine is still in its
infancy and will require extensive valida-
tion and assessment of variables before it
is anywhere near reaching its full potential
in routine diagnostics.
Conclusion
With a time-to-result of hours rather than
days, molecular detection promises speed
in addition to improved specificity and
sensitivity. However, given that molecular
biology targets DNA rather than live
cells, the approach can sometimes be too
sensitive—making no distinction between
DNA from live or dead cells. Ultimately,
the effective use of molecular diagnostic
methods will rely on the same criteria as
for traditional culture based methods—
maintaining an affordable level of sensiti-
vity and specificity, and seeking not to
exclude the less common pathogens, while
selecting for those deemed to be the most
significant in human infectious disease.
Diagnostic molecular biology is argu-
ably the fastest growing area in current
laboratory-based medicine, and has the
potential to change the course of clinical
medicine dramatically over the next dec-
ade. Although personalized medicine may
not be ready for immediate implementa-
tion in the clinical laboratories as yet, it is
likely that its progression will be coupled
with the advances seen in molecular
methods, thus allowing us to define the
scope and nature of human biological
variation and permit us to target medical
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treatment to those who will most likely
benefit. In this era of “omics” technolo-
gies, we may soon be able to move away
from the “one test, one pathogen” para-
digm toward multiplex approaches to
infectious disease diagnosis and in doing
so, revolutionize clinical diagnostics and
ultimately improve patient care.
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